Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
bioAffinity Technologies, Inc. (BIAF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: BIAF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -28.87% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.42M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 1 | Beta 2.56 | 52 Weeks Range 0.16 - 2.99 | Updated Date 06/29/2025 |
52 Weeks Range 0.16 - 2.99 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.71 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -110.55% | Operating Margin (TTM) -141.73% |
Management Effectiveness
Return on Assets (TTM) -88.58% | Return on Equity (TTM) -290.85% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9310480 | Price to Sales(TTM) 0.96 |
Enterprise Value 9310480 | Price to Sales(TTM) 0.96 | ||
Enterprise Value to Revenue 1.06 | Enterprise Value to EBITDA -0.21 | Shares Outstanding 28459500 | Shares Floating 21528674 |
Shares Outstanding 28459500 | Shares Floating 21528674 | ||
Percent Insiders 24.52 | Percent Institutions 1.8 |
Analyst Ratings
Rating 1 | Target Price 6 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
bioAffinity Technologies, Inc.
Company Overview
History and Background
bioAffinity Technologies, Inc. is a biotechnology company focused on cancer diagnostics and therapeutics. Founded in 2014, it has focused on developing and commercializing CyPathu00ae Lung, a non-invasive test for early-stage lung cancer detection.
Core Business Areas
- Diagnostics: bioAffinity Technologies' primary focus is on developing and commercializing diagnostic tests for early cancer detection. Their lead product is CyPathu00ae Lung.
- Therapeutics: While diagnostics is primary, bioAffinity is researching therapeutic applications based on their platform technology.
Leadership and Structure
Maria Zannes serves as the President and CEO. The company operates with a small team focused on research, development, and commercialization.
Top Products and Market Share
Key Offerings
- CyPathu00ae Lung: CyPathu00ae Lung is a non-invasive test designed to detect early-stage lung cancer by analyzing patient sputum samples. Market share data is currently limited due to the test's relatively recent commercialization. Competitors include companies offering liquid biopsies or other early lung cancer detection methods (e.g., Veracyte, Biodesix).
Market Dynamics
Industry Overview
The cancer diagnostics industry is rapidly growing, driven by advancements in technology and increasing demand for early and accurate detection. Liquid biopsy and non-invasive approaches are gaining prominence.
Positioning
bioAffinity Technologies is positioned as a player in the early lung cancer detection space, focusing on a non-invasive sputum-based approach. Their competitive advantage lies in the potential for high sensitivity and specificity.
Total Addressable Market (TAM)
The TAM for lung cancer diagnostics is substantial, estimated in the billions of dollars annually. bioAffinity is positioned to capture a portion of this market with its CyPathu00ae Lung test, contingent on successful commercialization and adoption.
Upturn SWOT Analysis
Strengths
- Non-invasive early detection method
- Potential for high sensitivity and specificity
- Proprietary CyPathu00ae technology
Weaknesses
- Limited commercialization history
- Small company size and resources
- Dependence on a single product (CyPathu00ae Lung)
Opportunities
- Expanding CyPathu00ae Lung to new markets
- Developing new diagnostic tests based on the CyPathu00ae platform
- Partnerships with hospitals and cancer centers
Threats
- Competition from established diagnostic companies
- Regulatory hurdles for new diagnostic tests
- Reimbursement challenges from payers
Competitors and Market Share
Key Competitors
- VCYT
- ALDX
- NVGN
Competitive Landscape
bioAffinity Technologies faces competition from larger, more established diagnostic companies. Its advantages include its non-invasive approach and proprietary technology. Disadvantages include its limited resources and commercial experience.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the company's stage of development.
Future Projections: Future growth projections are dependent on the successful commercialization of CyPathu00ae Lung and the development of new products.
Recent Initiatives: Recent initiatives include expanding CyPathu00ae Lung to new markets and conducting clinical studies to demonstrate its efficacy.
Summary
bioAffinity Technologies is a small, early-stage biotechnology company focused on early lung cancer detection. The company's CyPathu00ae Lung test holds promise, but it faces challenges in commercialization and competition from larger players. Successful execution of their growth strategy and expansion into new markets is critical for future success. The company needs to effectively demonstrate the value of its product and manage its resources carefully.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
- Analyst estimates
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investors should conduct their own due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About bioAffinity Technologies, Inc.
Exchange NASDAQ | Headquaters San Antonio, TX, United States | ||
IPO Launch date 2022-09-01 | Founder, President, CEO & Director Ms. Maria Zannes J.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 57 | Website https://www.bioaffinitytech.com |
Full time employees 57 | Website https://www.bioaffinitytech.com | ||
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.